Facebook
Twitter
LinkedIn
ForwardMultiple Myeloma (MM) ECHO®: Advancing RRMM Care Through Communities of Practice: Educating Community-Based Hematologic/Oncologic Teams on the Use of BCMA-Directed BsAbs
Welcome to the 2025 – 2026 MM ECHO®!
Multiple Myeloma (MM) ECHO®:
Advancing RRMM Care Through Communities of Practice: Educating Community-Based Hematologic/Oncologic Teams on the Use of BCMA-Directed BsAbs
The six MM ECHO® sessions are scheduled to take place between 7 - 8pm ET
| September 11, 2025 | January 8, 2026 |
| October 9, 2025 | March 12, 2026 |
| November 13, 2025 | April 16, 2026 |
Background
Despite tremendous advances in the last decade or so, MM remains incurable, with poor outcomes, a heavy treatment burden, reduced quality and length of life, and a disproportionate burden on people with African ancestry. Because all patients eventually relapse, new therapeutic options are continuously needed. As a result, it is imperative that care teams remain as current as possible with information regarding new therapies and treatment strategies for this incredibly challenging disease.
Community hematologists/oncologists provide about 80% of cancer care in the US, treating a wide variety of malignancies. In fact, according to a 2024 American Society of Clinical Oncology (ASCO) case study, community-based practices are preferred over large hospitals and academic centers for cancer treatment. The reasons? More personalized care, greater convenience and accessibility, greater cost-effectiveness, and a collaborative approach. As use of BCMA-directed BsAbs in patients with MM is still quite new, experience, particularly in the community setting, is limited, and a variety of barriers exist to bringing these treatments to patients. Participating in a community of practice is an effective model for achieving quality outcomes by reducing barriers to access, fostering collaboration, and improving knowledge of guidelines in cancer care.
Learning Objectives:
At the conclusion of this learning activity, participants will be better able to:
- Characterize the safety and efficacy of BCMA-directed BsAbs for the treatment of MM.
- Appropriately incorporate BCMA-directed BsAbs into cases of patients with MM that are representative of clinical practice.
- Establish and follow workflows and lines of communication for monitoring and managing BCMA BsAb treatment-related adverse events (TRAEs).
- Summarize the importance and benefits of CoPs to providing coordinated, multidisciplinary, and interprofessional care for patients with MM receiving BCMA-directed BsAbs.
Key Reasons to Attend:
- Learn ways to collaborate with other members of the healthcare team to promptly incorporate BCMA-directed BsAbs into patient care.
- Review the safety standards of BsAbs for treating multiple myeloma, as well as the benefits and limitations of this approach.
- Establish a Community of Practice (CoP) in the national community cancer setting.
- Discuss actual patient cases as submitted by you and your co-learners!
What is Project ECHO®?
The Project ECHO® model was developed in 2003 by the University of New Mexico Health Sciences Center with the goal of democratizing implementation of best practices for healthcare to under-resourced people by providing training and mentorship to transform and sustain strong health systems where every person has fast access to the highest quality healthcare. ECHO is a knowledge and best-practice-sharing model with regularly occurring virtual sessions that link expert multidisciplinary and interprofessional teams (hubs) with community-based clinicians, often from rural or under-resourced communities (participants) via videoconferencing. Each session includes a foundational didactic presentation provided by the hub faculty and participants present deidentified real cases to the hub team, and each other, for discussion and recommendations, promoting mentoring and peer-to-peer learning within the network.
Participants learn from one another, as knowledge is tested and refined. This continuous loop of learning, mentoring, and peer support is what makes ECHO unique, with a long-lasting impact far beyond that of an in-person training, webinar, or e-learning course. Come to ECHO being prepared to share, engage, and fully participate in this “all teach, all learn” environment.
Directions to Register:
- To register for the sessions, click on "Register" above
- Choose the sessions you wish to attend
- You will receive a confirmation email with a calendar invite for each session
Claiming Credit:
- Complete each session-specific evaluation, which is required to claim credit.
- When you are in a session, to return to this Program Overview page, click the title in red text.
Collaboration Statement:
This ECHO series was developed by Boston University Chobanian & Avedisian School of Medicine in collaboration with the American Academy of Physician Associates, the Association of PAs in Oncology, HealthTree Foundation, and Med-IQ.
Grantor Acknowledgement:
This activity is supported by educational grants from Pfizer Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclaimer:
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
© Trustees of Boston University, 2025
ECHO Sessions
All sessions: 7-8 pm ET / 6-7 pm CT / 5-6 pm MT / 4-5 pm PT
September 11, 2025
BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Mechanisms of Action, Clinical Efficacy, and Emerging Therapeutics
Topic: Introduction to BCMA-directed bispecific antibodies, approved and investigational agents
Speaker: Raphael E. Szalat, MD, PhD
October 9,2025
Prevention, Monitoring, and Management of Adverse Events Associated With BCMA-Directed Bispecific Antibodies in Multiple Myeloma
Topic: Monitoring and managing adverse events of bispecific antibodies
Speaker: Sara Scott, PharmD, BCOP
November 13, 2025
BCMA-Directed Bispecific Antibodies in Multiple Myeloma: Bridging Academic and Community Practice
Topic: Creating communities of practice
Speaker: Camille Edwards, MD
January 8, 2026
Quality of Life and Patient Experience With BCMA-Directed Therapies in Multiple Myeloma
Topic: The patient perspective
Speaker: Jenny Ahlstrom
March 12, 2026
BCMA-Directed BsAbs in Multiple Myeloma: Overcoming Barriers to Care
Topic: Overcoming barriers to care
Speaker: Britney Bell, MD
April 16, 2026
Integrating BCMA-Directed Bispecific Antibodies Into the Treatment Algorithm for Multiple Myeloma
Topic: Clinical trials and real-world data for BCMA-directed bispecific antibodies
Speaker: Ajay K. Nooka, MD, MPH
Hub Team
Jenny Ahlstrom
Chief Executive Officer
HealthTree Foundation
Jenny Ahlstrom is a wife, mother of 6 and multiple myeloma patient diagnosed in 2010. In her own myeloma journey, she identified gaps in services she believed could help patients better navigate their care while inviting patients to help accelerate a myeloma cure. Jenny grew up in the San Francisco Bay Area, working for Hewlett Packard and then IBM as a mid-range Systems Engineer and Marketing Rep for healthcare software. She has been involved with tech startups over the last 30 years, supporting her husband Paul who is an entrepreneur, venture capitalist and private equity investor. Together, they used their tech and startup experience to solve significant problems in cancer research through the lens of a patient.
After her diagnosis, Jenny launched the HealthTree Foundation in 2012 to create new strategies and approaches to accelerate research using cutting-edge technology. This included the creation of novel software platforms called HealthTree Cure Hub (for patients) and HealthTree Research Hub (for researchers).
Ms. Jenny Ahlstrom has no relevant financial relationships to disclose.
Britney N. Bell, MD
Assistant Professor, Hematology/Oncology
Boston University Chobanian & Avedisian School of Medicine
Affiliate Faculty, Center for Forced Displacement
Boston University
Boston, MA
Britney N. Bell, MD, is a clinical researcher committed to advancing equitable cancer care by designing accessible, patient-centered solutions for historically marginalized communities. With a focus on human-centered design and implementation science, Bell develops innovative strategies to transform the patient experience and ensure care is tailored to diverse needs. Her work centers on expanding disease education across multiple contexts to enhance communication between patients, providers, and the healthcare system. She is especially passionate about applying these approaches to improve risk communication, foster community engagement, and build capacity for populations affected by hematologic diseases.
Dr. Britney Bell has no relevant financial relationships to disclose.
Jessica Jeune, BSN, RN
Nurse Navigator
Boston Medical Center
Boston, MA
Jessica Jeune, RN, has been working at Boston Medical Center for the last 20 years. She started working as a certified nursing assistant in 2005 while going to nursing school at UMass Boston, where she graduated with her BSN. Jeune worked as a registered nurse in the float pool for 9 years, where she perfected her hands-on patient skills and interdisciplinary communication. She then transitioned to become a nurse in the hematology/oncology clinic, where she has been working the last 9 years. She is now permanent charge nurse on this unit, where she can further grow and specialize her nursing skills. Jeune’s professional passion involves caring for the underserved, low-income population of patients, paralleling the mission of Boston Medical Center.
Ms. Jessica Jeune has no relevant financial relationships to disclose.
Ajay K. Nooka, MD, MPH
Program Co-Chair
Professor, Department of Hematology and Medical Oncology
Director, Myeloma Program
Associate Director, Clinical Research
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA
Ajay K. Nooka, MD, MPH, is a professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University. He earned his medical degree from Andhra Medical College in India before relocating to the United States. He received his master’s in public health from the University of Texas School of Public Health in Houston, Texas, and then completed his internship and residency at the Northeastern Ohio University College of Medicine. He pursued a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia, where he also served as chief fellow before he joined faculty.
Board certified in hematology and medical oncology, Nooka is the director of the Myeloma Program in the Department of Hematology and Oncology at Emory and primarily focuses on multiple myeloma treatment and research. He is also the associate director of clinical research at Winship Cancer Institute. He is involved in numerous professional organizations, including the International Myeloma Working Group of the International Myeloma Society, the American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapy. Nooka’s interests as a clinical investigator focus on multiple myeloma and bone marrow transplant. His research interests include integrating molecular and clinical data to risk-stratify myeloma and to evaluate newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients.
In addition to leading several investigator-initiated and industry-sponsored clinical trials, he is a recipient of several awards and grants and has published more than 300 articles and abstracts in high-quality peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Blood, Leukemia, Lancet Oncology, Blood Advances, Blood Cancer Journal, and Cancer. He serves as a section editor for Cancer, is associate editor for Clinical Lymphoma, Myeloma and Leukemia and is on the editorial board of the American Journal of Clinical Oncology. He is an invited or ad hoc reviewer for several prestigious journals including Journal of Clinical Oncology, Lancet Oncology, Leukemia, Cancer, Blood Advances, Blood Cancer Journal, American Journal of Hematology, British Journal of Hematology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation.
Disclosures: Dr. Ajay Nooka, program Co-Chair, is a consultant for Adaptive Biotechnologies, AstraZeneca, Cellectar Biosciences, GlaxoSmithKline, Janssen, K36 Therapeutics, KITE Therapeutics, ONK Therapeutics, OPNA, Pfizer Inc., Sanofi and Sebia. He also receives grant research support from Aduro Biotech, Amgen, Arch Oncology, Bristol Meyers Squibb, Cellectis, Genentech, GlaxoSmithKline, Janseen, OPNA, Karyopharm, Kite Pharma, Merck, Pfizer Inc., and Takeda.
Jaime Román III, MPAS, PA-C
Physician Assistant
Texas Oncology-Plano West
Plano, TX
Jaime Román III, MPAS, PA-C, is a physician assistant currently working at Texas Oncology-Plano West. Originally from Bryan, Texas, Román graduated from Texas A&M University in 2009. He then went on to finish his clinical studies at UT Southwestern School of Health Professions, earning his master's in physician assistant studies in December 2012. He began working as an outpatient physician assistant at the Simmons Comprehensive Cancer Center at UT Southwestern in Dallas, Texas, focusing on hematologic malignancies and bone marrow transplantation starting in January 2013. He was promoted to Lead Advanced Practice Provider at UT Southwestern in October of 2016. After 2 years in this role, Román transitioned to the community oncology setting in Plano.
His clinical interests include chronic leukemias, epigenetics in cancer, genomic mutations, and targets for cancer therapy. He enjoys speaking and education and is an active lecturer for new advanced practice providers entering the US Oncology Network as well as for physician assistant students at UT Southwestern.
Disclosures: Mr. Roman is a speaker for Abbvie, AstraZeneca, EMD Serono, Janssen, Pfizer Inc., Pharmacosmos, Pharmacyclics, PharmaEssentia.
Sara Scott, PharmD, BCOP
Oncology Clinical Pharmacy Specialist
Winship Cancer Institute
Emory Healthcare
Atlanta, GA
Sara Scott, PharmD, BCOP, is a board-certified clinical pharmacy specialist in multiple myeloma at Emory Winship Cancer Institute. She received a BS in biomedical engineering at the University of Utah. She completed her PharmD at The University of North Carolina at Chapel Hill. After school, she completed her PGY1 pharmacy residency at Vanderbilt University Medical Center in Nashville, Tennessee, and her PGY2 oncology pharmacy residency at The University of Kansas Health System in Kansas City, Kansas. She is an active member of Hematology/Oncology Pharmacy Association and the American Society for Transplantation and Cellular Therapy. Her professional interests include multiple myeloma, bone marrow transplant, and cellular therapy.
Dr. Sara Scott is a consultant for GlaxoSmithKline, J&J Innovative Medicine, Pfizer Inc., and Sanofi.
Raphael E. Szalat, MD, PhD
Program Co-Chair
Assistant Professor of Medicine
Director, Multiple Myeloma Program
Director, Stem Cell Transplant Program
Section of Hematology and Medical Oncology
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Boston, MA
Raphael E. Szalat, MD, PhD received his medical training at the University of Pierre and Marie Curie in Paris, France. After internal medicine residency, Szalat specialized in immunology and plasma cell disorders, including multiple myeloma and monoclonal gammopathies of clinical significance, and became a clinical assistant professor in the Department of Immuno-Hematology in Saint-Louis Hospital, Paris. He next completed a PhD and postdoc in hematology, studying genomics in multiple myeloma at the Dana-Farber Cancer Institute, Harvard Medical School, in collaboration with La Sorbonne University, Paris, and a clinical fellowship in hematology and oncology at the Boston University Medical Center.
Dr. Szalat currently serves as director of the Multiple Myeloma Program and the Stem Cell Transplant Program at the Boston University Medical Center. His main interests are developing myeloma clinical trials and performing basic and translational research on multiple myeloma and other plasma cell disorders, including AL amyloidosis and other monoclonal gammopathies of clinical significance.
Disclosures: Dr. Raphael Szalat, program Co-Chair, is a consultant for Johson & Johnson.
Faculty Consultant Planner
Camille Edwards, MD
Assistant Professor of Medicine
Boston University Chobanian & Avedisian School of Medicine
Boston Medical Center
Boston, MA
Camille Edwards, MD, is an assistant professor of medicine at the Boston University Chobanian & Avedisian School of Medicine (BUSM )and Boston Medical Center (BMC). After internal medicine residency, Edwards completed her hematology and oncology fellowship at BUSM/BMC, obtaining rigorous clinical and research training through the comprehensive Cancer Center, the world-renowned BU Amyloidosis Center, and the Center for Regenerative Medicine. As a physician-scientist and hematologist, her clinical and research platforms are multifaceted. In her clinical capacity, she not only provides care for patients with hematologic diseases but also advocates for patients through peer education and community-based patient education programs. Her translational research focuses on deciphering the socioenvironmental and molecular context of plasma cell disorders. Edwards’s work has led to several prestigious awards from the American Society of Hematology, the International Myeloma Foundation, and the National Institutes of Health's Artificial Intelligence/Machine Learning Consortium to Advance Health Equity and Researcher Diversity.
Dr. Camille Edwards has no relevant financial relationships to disclose.
Off-Label Discussion
Dr. Nooka will discuss the unlabeled/investigational use of etentamig and linvoseltamab.
Dr. Scott may include investigational uses, including combination therapies.
All other faculty members do not plan on discussing the unlabeled/investigational use of any commercial products.
Planning Committee and Disclosures
Christie Avraamides, PhD, Med-IQ’s Director of Clinical Content, Catherine Bretz, Med-IQ's Vice President of Strategic Partnerships, Whitney Stevens, Med-IQ’s Sr. Director, Project Management, have no relevant financial relationships to disclose.
The planning team from Boston University Center for Continuing Education, including Linda Baer, Grants Manager, Michael Burk, Senior Program Manager, Alison Li, Program Manager and Julie White, Director, do not have any relevant financial relationships to disclose.
The planning team members including Leah Eberhardt and Eric Peterson of the American Academy of Physician Associates (AAPA), Dawn McKnight of the Association of Physician Associates in Oncology (APAO), and Cynthia Cahoon from Healthtree Foundation, have no relevant financial relationships to disclose.
Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.
Accreditation Statement
This activity is developed as a joint collaboration among Boston University Chobanian & Avedisian School of Medicine, Med-IQ, the AAPA, the Association of PAs in Oncology (APAO), and HealthTree Foundation.
In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Med-IQ. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Accreditation
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Please note that 6.0 credits are based on participation in all six ECHO sessions.
American Board of Internal Medicine Maintenance of Certification (MOC) Part 2 Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.
Please note that 6.0 credits are based on participation in all six ECHO sessions.
Nurse Accreditation
Nursing Contact Hours: 6.0, of which 6.0 are eligible for pharmacology credit.
Please note that 6.0 credits are based on participation in all six ECHO sessions.
Pharmacist Accreditation
This activity is approved for 6.0 CPE credits.
Please note that 6.0 credits are based on participation in all six ECHO sessions.
Physician Associate Accreditation
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Please note that 6.0 credits are based on participation in all six ECHO sessions.
Available Credit
- 6.00 AAPA Category I CME
- 6.00 ABIM Medical Knowledge
- 6.00 ACPE Pharmacy
- 6.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 6.00 ANCC
- 6.00 ANCC Pharmacology
- 6.00 Participation
Please check off the sessions you wish to attend. Once enrolled, you will receive an email for each session with a calendar invite to save to your calendar. Once you have participated in the meeting, you can click on the link to the session in your calendar invite and proceed to complete the evaluation and claim credit.
This is the Program Overview page which lists all the available sessions in this ECHO® program. Each session contains a session-specific evaluation, which is required in order to claim credit. When you are in a session to return to the overview page, click on the title in red on the right side of the page.